Cellectis Exits Lasme-Cel And Eti-Cel Development To Focus On In Vivo Gene Editing Pipeline, Targeting Cash Runway Extension Into H2 2028
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by continuing existing
Share
Why It Matters
Cellectis stopped work on two older medicine projects. Now the company is focusing all its money on newer gene editing treatments to last until late 2028.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.